Tarek Mohammed Mamdouh Abdelfatah Abdelghany

Dr. Tarek Mohammed Mamdouh Abdelfatah Abdelghany


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2024 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
ALAlistair C. Leitch
Alistair C. Leitch
TATarek Mohammed Mamdouh Abdelfatah Abdelghany
Tarek Mohammed Mamdouh Abdelfatah Abdelghany
ACAlex Charlton
Alex Charlton
MCMartin Cooke
Martin Cooke
MWMatthew Wright
Matthew Wright
Environmental sampling around a landfill site in the UK previously identified the methylimidazolium ionic liquid, 1-octyl-3-methylimidazolium (M8OI), in the soil. More recently, M8OI was shown to be detectable in sera from 5/20 PBC patients and 1/10 controls and to be oxidised on the alkyl chain in the human liver. The objective of this study was to examine the metabolism of M8OI in humans in more detail. In human hepatocytes, M8OI was mono-oxygenated to 1-(8-Hydroxyoctyl)-3-methyl-imidazolium (HO8IM) then further oxidised to 1-(7-carboxyheptyl)-3-methyl-1H-imidazol-3-ium (COOH7IM). The addition of ketoconazole—in contrast to a range of other cytochrome P450 inhibitors—blocked M8OI metabolism, suggesting primarily CYP3A-dependent mono-oxygenation of M8OI. Hepatocytes from one donor produced negligible and low levels of HO8IM and COOH7IM, respectively, on incubation with M8OI, when compared to hepatocytes from other donors. This donor had undetectable levels of CYP3A4 protein and low CYP3A enzyme activity. Transcript expression levels for other adult CYP3A isoforms—CYP3A5 and CYP3A43—suggest that a lack of CYP3A4 accounted primarily for this donor’s low rate of M8OI oxidation. Insect cell (supersome) expression of various human CYPs identified CYP3A4 as the most active CYP mediating M8OI mono-oxygenation, followed by CYP3A5. HO8IM and COOH7IM were not toxic to human hepatocytes, in contrast to M8OI, and using a pooled preparation of human hepatocytes from five donors, ketoconazole potentiated M8OI toxicity. These data demonstrate that CYP3A initiates the mono-oxygenation and detoxification of M8OI in adult human livers and that CYP3A4 likely plays a major role in this process.

18 February 2025 in Chemosphere
Verified
Journal Article
Open access
TATarek Mohammed Mamdouh Abdelfatah Abdelghany
Tarek Mohammed Mamdouh Abdelfatah Abdelghany
JBJessica Bosak
Jessica Bosak
ALAlistair C. Leitch
Alistair C. Leitch
ACAlex Charlton
Alex Charlton
LFLanyu Fan
Lanyu Fan
MWMatthew Wright
Matthew Wright
Methylimidazolium ionic liquids (MILs) are solvents used in an increasing variety of industrial applications. Recent studies identified the 8C MIL (M8OI) contaminating the environment, detected exposure in humans and proposed M8OI to be a potential trigger for the autoimmune liver disease primary biliary cholangitis (PBC). To gain a better understanding of any PBC trigger mechanism(s), the interaction of M8OI with mitochondria has been examined. M8OI inhibited oxygen consumption in intact cells and induced cell death (IC50%-10 μM). Results from permeabilized cells indicated M8OI inhibits the mitochondrial electron transport chain at complex I, not complexes II, III or IV. Accordingly, succinate supported mitochondrial oxygen consumption and reduced cell death in the presence of M8OI. M8OI inhibited NADH oxidation by both mitochondrial membranes and purified complex I with IC50% values of 470 μM and 340 μM respectively. Based on direct determinations of M8OI in non-mitochondrial and mitochondrial compartments, toxic M8OI concentrations were estimated to result in mitochondrial concentrations commensurate with complex I inhibition. Mitochondrial accumulation followed by complex I inhibition is therefore a possible molecular initiating event for M8OI-dependent cell death. NADH oxidation by purified complex I in combination with a flavin-site electron acceptor was not inhibited by M8OI, indicating no interaction of M8OI at the NADH-binding active site. Modelling supported M8OI binding to the ubiquinone-binding site. By inhibiting turnover, M8OI also gave rise to increases in complex-I-linked reactive oxygen species. However, inhibitors of oxidative stress did not affect M8OI-mediated cell death. The metabolic consequences of M8OI-mediated complex I inhibition, not increased reactive oxygen species production, are therefore the likely cause of apoptotic cell death. Understanding the effects on complex I and the pathways activated and leading to cell death may be informative regarding mitochondrial stress, cell death and diseases such as PBC.

17 June 2026 in Journal of Xenobiotics
Verified
Journal Article
Open access
PDF file
TATarek Mohammed Mamdouh Abdelfatah Abdelghany
Tarek Mohammed Mamdouh Abdelfatah Abdelghany
ABAlaa A. Budastour
Alaa A. Budastour
Ahmed KamelAhmed Kamel
Ahmed Kamel
SISherehan Ibrahim
Sherehan Ibrahim
ACAlex Charlton
Alex Charlton
MWMatthew Wright
Matthew Wright
M8OI is a cytotoxic methylimidazolium ionic liquid solvent through its binding to the ubiquinone binding site on complex I of the mitochondrial electron transport chain. Given the overlap in terms of toxic mechanism of action with the pesticide rotenone, the potential neurotoxic effects of M8OI were examined. In vitro, cytotoxicity and mitochondrial function were assessed in SH-SY5Y cells by measuring MTT reduction and oxygen consumption/extracellular acidification using a Seahorse analyser. SH-SY5Y cells were sensitised to M8OI toxicity by replacing medium glucose with galactose. Glucose protected the cells from M8OI toxicity, whereas galactose showed no clear dose–response protection. M8OI induced a dose-dependent reduction in oxygen consumption rate with a compensatory increase in extracellular acidification rate, consistent with inhibition of mitochondrial oxidative phosphorylation and a shift toward glycolysis. In vivo, rats were orally exposed via drinking water for 20 weeks and assessed using behavioural tests. In addition, the concentrations of M8OI and its metabolites were quantified by LC–MS in rat brain and other tissues. In rats, M8OI concentrations were ~30-fold higher in kidney than brain, and brain levels were at least 100-fold lower than the concentrations that affected SH-SY5Y cell viability in vitro. However, based on open field tests, M8OI exposure suppressed motor activity without any anxious behaviours. The cytotoxicity of M8OI in SH-SY5Y neuroblastoma cells was associated with metabolic mitochondrial dysfunction. However, the neurobehavioural changes observed in orally exposed rats occurred at significantly lower brain concentrations than would be predicted to lead to neural cell death. Nevertheless, direct comparisons between acute in vitro exposures and chronic in vivo outcomes should be interpreted cautiously.

9 July 2026 in European Journal of Pharmacology
Verified
Journal Article
Open access
LALamiaa A. Ahmed
Lamiaa A. Ahmed
KAKhaled F. Al-Massri
Khaled F. Al-Massri
SHShireen A. Hedya
Shireen A. Hedya
TATarek Mohammed Mamdouh Abdelfatah Abdelghany
Tarek Mohammed Mamdouh Abdelfatah Abdelghany
Preconditioning has emerged as a promising approach in the management of ischaemic heart diseases. Ischaemic and pharmacological preconditioning have shown their ability to reduce myocardial infarct size and preserve cardiac function in various experimental and clinical settings. The underlying protective mechanisms of preconditioning involve the activation of signalling cascades that promote cell survival, inhibit cell damage and improve cellular energetics. However, the presence of cardiovascular co-morbidities such as ageing, diabetes, hyperlipidaemia, hypertension and chronic kidney disease is known to impair preconditioning stimuli and limit their effectiveness upon translation to clinical practice. This review discusses the impact of these co-morbidities on preconditioning signalling cascades and strategies to overcome this impairment by targeting comorbidity-specific pathways; using various preconditioning triggers, employing combined therapies and amplifying preconditioning stimuli. Additionally, bridging the gap between experimental and clinical studies through well-designed clinical trials is crucial for guaranteeing the feasibility and efficacy of preconditioning interventions in cardiovascular patients with diverse comorbidities.